RxDoctor Payments Data

Jonathan Foote, MD

Gynecologic Oncology · Charleston, SCNPI 1477781334

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.8% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 26.3% of the total. Reporting peaked in 2019 at $847 and has fallen 81.5% since, to $156 in 2025.

$3,288in general payments, 2019–2025

Across 134 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$864
  • Eisai Inc.$506
  • Merck$463
  • Clovis Oncology, Inc.$375
  • GSK$201
  • Seagen Inc.$142
  • plus $737 from 17 others

What the payments were for

  • Food & beverage$3,18297%
  • Education$1063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$37,483
Medicare patients
163
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib36$350,882
Clobetasol Propionate13$925
Dexamethasone27$607
Imiquimod13$533
Ondansetron OdtOndansetron34$448
Lidocaine-PrilocaineLidocaine/Prilocaine18$218
Gabapentin16$150
Megestrol Acetate13$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$864$350,88236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecologic oncology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other gynecologic oncology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →